AKBA - Akebia Therapeutics, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Cambridge,
United States
Type: Equity
AKBA price evolution
AKBA
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jul 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $42.92 | $46.53 | $53.57 | $56.95 |
| Short term investments | ||||
| Net receivables | $39.29 | $22.59 | $19.57 | $17.78 |
| Inventory | $15.69 | $18.44 | $20.91 | $20.6 |
| Total current assets | $118.15 | $109.6 | $118.45 | $120.72 |
| Long term investments | ||||
| Property, plant & equipment | $16.05 | $17.44 | $18.81 | $32.77 |
| Goodwill & intangible assets | $95.09 | $104.1 | $113.11 | $118.13 |
| Total noncurrent assets | $123.55 | $125.4 | $135.26 | $156.14 |
| Total investments | ||||
| Total assets | $241.7 | $235 | $253.71 | $276.86 |
| Current liabilities | ||||
| Accounts payable | $14.63 | $9.04 | $11.78 | $12.58 |
| Deferred revenue | $83.39 | $83.64 | $83.92 | $84.09 |
| Short long term debt | $17.5 | $8 | $24 | $24 |
| Total current liabilities | $99.87 | $79.7 | $92.18 | $82.94 |
| Long term debt | $26.13 | $44.84 | $29.97 | $53.71 |
| Total noncurrent liabilities | $172.42 | $194.72 | $188.34 | $208.27 |
| Total debt | $43.63 | $52.84 | $53.97 | $77.71 |
| Total liabilities | $272.29 | $274.42 | $280.52 | $291.21 |
| Shareholders' equity | ||||
| Retained earnings | -$1608.95 | -$1609.56 | -$1595.08 | -$1579.13 |
| Other shareholder equity | $0.01 | $0.01 | $0.01 | $0.01 |
| Total shareholder equity | -$30.58 | -$39.42 | -$26.81 | -$14.35 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Jan 2022 | 31 Jan 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $42.92 | $90.47 | $149.8 | $228.7 |
| Short term investments | $39.99 | |||
| Net receivables | $39.29 | $39.18 | $50.88 | $26.9 |
| Inventory | $15.69 | $21.76 | $38.2 | $61 |
| Total current assets | $118.15 | $184.95 | $272.01 | $371.4 |
| Long term investments | ||||
| Property, plant & equipment | $16.05 | $34.37 | $40.61 | $35.5 |
| Goodwill & intangible assets | $95.09 | $127.14 | $163.18 | $199.22 |
| Total noncurrent assets | $123.55 | $166.88 | $253.54 | $272.7 |
| Total investments | $39.99 | |||
| Total assets | $241.7 | $351.83 | $525.55 | $644.1 |
| Current liabilities | ||||
| Accounts payable | $14.63 | $18.02 | $33.59 | $41.3 |
| Deferred revenue | $83.39 | $88.03 | $42.38 | $40.56 |
| Short long term debt | $17.5 | $32 | $97.54 | |
| Total current liabilities | $99.87 | $124.76 | $256.49 | $187.1 |
| Long term debt | $26.13 | $34.08 | $33.7 | $96.4 |
| Total noncurrent liabilities | $172.42 | $217.73 | $192.6 | $209.38 |
| Total debt | $43.63 | $95.04 | $131.25 | $121 |
| Total liabilities | $272.29 | $342.49 | $449.09 | $396.5 |
| Shareholders' equity | ||||
| Retained earnings | -$1608.95 | -$1552.91 | -$1460.35 | -$1177.5 |
| Other shareholder equity | $0.01 | $0.01 | $0.01 | $0.01 |
| Total shareholder equity | -$30.58 | $9.34 | $76.46 | $247.62 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jul 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $56.2 | $42.05 | $40.13 | |
| Cost of revenue | $18.66 | $18.01 | $19.48 | |
| Gross Profit | $37.53 | $24.04 | $20.64 | |
| Operating activities | ||||
| Research & development | $9.87 | $13.33 | $19.69 | |
| Selling, general & administrative | $25.44 | $22.71 | $25.22 | |
| Total operating expenses | $32.92 | $37.07 | $45.58 | |
| Operating income | $4.61 | -$13.04 | -$24.94 | |
| Income from continuing operations | ||||
| EBIT | $2.03 | -$13.08 | -$24.66 | |
| Income tax expense | ||||
| Interest expense | $1.42 | $1.41 | $1.56 | |
| Net income | ||||
| Net income | $0.61 | -$14.49 | -$26.22 | |
| Income (for common shares) | $0.61 | -$14.49 | -$26.22 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $194.62 | $292.6 | $213.58 | $295.31 |
| Cost of revenue | $74.15 | $84.8 | $153.39 | $295.91 |
| Gross Profit | $120.47 | $207.81 | $60.18 | -$0.6 |
| Operating activities | ||||
| Research & development | $63.08 | $129.11 | $147.85 | $218.49 |
| Selling, general & administrative | $100.23 | $138.7 | $174.16 | $153.95 |
| Total operating expenses | $163.49 | $286.92 | $325.5 | $375.84 |
| Operating income | -$43.02 | -$79.11 | -$265.32 | -$376.44 |
| Income from continuing operations | ||||
| EBIT | -$45.89 | -$76.88 | -$262.9 | -$374.59 |
| Income tax expense | ||||
| Interest expense | $6.03 | $15.69 | $19.94 | $8.87 |
| Net income | ||||
| Net income | -$51.92 | -$92.56 | -$282.84 | -$383.46 |
| Income (for common shares) | -$51.92 | -$92.56 | -$282.84 | -$383.46 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Net income | $0.61 | -$14.49 | -$11.17 | -$26.22 |
| Operating activities | ||||
| Depreciation | $14.84 | $9.14 | $9.03 | $8.83 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $1.51 | $1.82 | $3.49 | $2.49 |
| Total cash flows from operations | -$2.31 | -$7.17 | $3.63 | -$17.54 |
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | ||||
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $6.71 | $0.05 | $0.03 | |
| Net borrowings | -$8 | -$8 | -$16 | |
| Total cash flows from financing | -$1.29 | $0.05 | -$8 | -$15.97 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$3.6 | -$7.12 | -$4.37 | -$33.5 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$51.92 | -$92.56 | -$282.84 | -$383.46 |
| Operating activities | ||||
| Depreciation | $41.85 | $35.28 | $36.13 | $31.55 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $9.32 | $17.85 | $22.73 | $24.46 |
| Total cash flows from operations | -$23.38 | -$73.15 | -$252.97 | -$110.39 |
| Investing activities | ||||
| Capital expenditures | -$0.11 | -$0.06 | -$0.32 | |
| Investments | $40 | -$39.69 | ||
| Total cash flows from investing | -$0.11 | $39.94 | -$40 | |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $6.79 | $7.6 | $88.95 | $211.75 |
| Net borrowings | -$32 | -$33 | $19.98 | |
| Total cash flows from financing | -$25.21 | $14.6 | $133.73 | $231.72 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$48.59 | -$58.67 | -$79.29 | $81.33 |
News
Fundamentals
| Market cap | $266.58M |
|---|---|
| Enterprise value | $267.28M |
| Shares outstanding | 194.58M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | 1.84% |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | -8.71 |
| Book/Share | -0.16 |
| Cash/Share | 0.22 |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | -8.90 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 1.18 |
| Quick ratio | 1.03 |